A cell therapy preserves muscle structure and function in laboratory mice with a type of disease similar to Duchenne muscular ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug. 04, 2025 ...

Alfie from Leigh has a muscle wasting condition and is looking for signed rugby shirts to auction off to help him live out ...

Hansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with Duchenne muscular dystrophy (DMD) with Sarepta and Roche’s Elevidys ...

Dyne Therapeutics' DYNE-251 receives FDA breakthrough status for Duchenne muscular dystrophy treatment. Read more here.

Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular ...

SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.

Wave Life Sciences (WVE) stock gains as Canaccord Genuity launches its coverage with a Buy, citing multiple catalysts for the ...

Investing.com -- Dyne Therapeutics Inc (NASDAQ: DYN) stock rose 3.6% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its ...

Precision BioSciences Inc., a clinical-stage company developing gene editing therapies for diseases with high unmet need, has ...

After Loomer targeted surgeon general nominee and Kennedy ally Casey Means, Means’s brother, Calley, suggested that Loomer’s ...